Introduction
Transcript profiling has been used extensively to characterize the gene expression profiles of clinical samples and cell line models of prostate cancer in an attempt to identify genes associated with progression of the disease (Bubendorf et al., 1999; Dhanasekaran et al., 2001; Singh et al., 2002) . We extended the application of this strategy to identify genes that were specifically expressed in normal and malignant prostate tissue by incorporating a normal body atlas (NBA) of specimens from a wide variety of other normal tissues into the transcript profiling. The goal of this study was to identify novel targets with potential clinical utility that may also provide further insight into the underlying biology of this disease. Currently, therapy for localized prostate cancer is limited to radical prostatectomy (RP) and/or radiotherapy. Surgery alone is associated with a substantial risk of undesirable side effects, including impotence and urinary incontinence with 30% of patients developing recurrent disease, at which point they become essentially incurable. This stresses the need for innovative therapies that are based on molecular targets, as have been implemented for non-Hodgkins lymphoma and breast cancer in the form of specific monoclonal antibodies that target tumour-specific antigens (McLaughlin et al., 1998; Slamon et al., 2001) .
The zinc transporter, ZnT4, encodes a 430 amino-acid protein that was first isolated as the gene responsible for inherited zinc deficiency in the lethal milk mouse (Huang and Gitshier, 1997) . While its expression in several tissues, including mouse brain, mammary gland (Huang and Gitshier, 1997; Michalczyk et al., 2002) and rat intestinal epithelium (Murgia et al., 1999) , has been described, this is the first study to demonstrate the expression of ZnT4 in the human prostate. The function of ZnT4 in the prostate is unknown. However, normal and hyperplastic prostate tissues accumulate the highest levels of zinc of any soft tissue in the body (Zaichick et al., 1997) . In contrast, the zinc level in prostate cancer is markedly reduced. As zinc is a highly charged, hydrophilic species, mammalian cells require specialized plasma membrane transporters to mediate its uptake (McMahon and Cousins, 1998) .
The present report demonstrates reduced ZnT4 expression in the progression from normal and benign prostate tissue to malignant disease.
Results

Identification of ZnT4 as a gene expressed in human prostate and prostate cancer
A cohort of 74 RP was collected for molecular profiling using the Eos Hu03 oligonucleotide array. These samples represent localized prostate cancer with Gleason grades ranging from 6 to 9 and median prostate specific antigen (PSA) levels of 8.8 ng/ml (range 3.1-90.4 ng/ml). Gene expression in these samples was compared to gene expression in 164 normal tissue samples representing 40 different body tissues, including four normal prostate samples. Over 200 gene clusters were identified as specifically expressed (or enriched) in normal prostate and/or prostate cancer. Further bioinformatics analysis for identification of these prostate tissue-enriched genes included mapping the probesets to gene clusters assembled using the Cluster Alignment Tool (DoubleTwist, Oakland, CA, USA), with gene identification confirmed by homology alignment with sequences in GenBank (http://www.ncbi.nlm.nih.gov/) and Unigene (http://www.ncbi.nlm.nih.gov/UniGene/ Hs.Home.html) using the Blast algorithm (http:// www.ncbi.nlm.nih.gov/BLAST/). Additional information and sequence confirmation were attained by mapping the gene to the human genome using the publically available site at the National Center for Biotechnology Information (NCBI) (http://www.ncbi. nlm.nih.gov/genome/guide/human/). Gene-coding sequences were then screened for potential cell surface molecules by searching the sequences for transmembrane domains and Pfam domains using the Simple Modular Architecture Research Tool (SMART, (http:// smart.embl-heidelberg.de/)).
One of the genes demonstrating prostate and prostate-cancer-specific expression was the zinc transporter ZnT4 (NCBI reference sequence NM_013309, GenBank AF025409). Using SMART, the ZnT4 protein sequence contained six potential transmembrane domains and exhibited the Pfam annotation of Cation_efflux, suggesting that ZnT4 is a membrane protein involved in the transport of divalent metal ions. Figure 1a shows ZnT4 mRNA expression in the prostate cancer samples with respect to the NBA. The data show a fivefold increase in the median ZnT4 level in prostate cancer (557 average intensity units) with respect to the 85th percentile of normal tissue expression (107 average intensity units). It should be noted that female tissues (ovary, breast, endometrium, cervix and uterus) were excluded from 75-76, aorta 77-78, aortic valve 79, artery 80, vein 81-82, bladder 83-89, ureter 90-91, bone marrow 92-95, brain 96-97, dorsalroot ganglia 98, cerebral cortex 99, spinal cord 100, vagus nerve 101, colonic epithelium 102-122, colon 123-128, colonic muscle 129-132, diaphragm 133-134, oesophagus 135-136, gall bladder 137, heart 138-140, kidney 141-148, liver 149-159, lung 160-165, lymph node 166-167, muscle 168-73, peripheral blood mononucleocytes 174-194, pancreas 195-200, prostate 201-204, rectum 205-206, small intestine ileum 207, small intestine jejunum 208-209, salivary gland 210, skin 211-213, small intestine 214-216, spleen 217-221, stomach 222-229, testis 230-231, thymus 232-233, thyroid 234, trachea 235-237 (Figure 1b) . However, the expression levels in LNCaP are significantly lower than those in the primary prostate cancer specimens.
ZnT4 localizes to intracellular vesicles and the plasma membrane
ZnT4 belongs to a family of multitransmembrane proteins that have been associated with intracellular vesicles and the plasma membrane (Palmiter and Findley, 1995; Palmiter et al., 1996a, b) . Structural analysis of ZnT4 predicts six transmembrane domains with short intervening loops and long amino-and carboxyl-termini on the same side of the membrane. To analyse the topology and subcellular localization of the ZnT4 protein, the full-length cDNA was cloned into a retroviral expression vector that provides an HA-tag at the carboxyl-terminus. Retrovirus encoding HA-tagged ZnT4 was produced in Cos7 cells and was used to generate mouse NIH3T3 cells, mouse fibroblast cells ( In order to confirm cell surface expression of ZnT4, intact NIH3T3 and MFC expressing ZnT4 were labelled with a water-soluble biotinylation reagent that is excluded from live cells. Biotinylated proteins were affinity purified from cell extracts using streptavidin gel and then probed with an anti-HA antibody by Western blotting (Figure 3a , b). The Western blot results show that ZnT4 was biotinylated on the cell surface. We conclude from these results that some ZnT4 is expressed at the cell surface as well as highly expressed in intracellular vesicles.
ZnT4 is expressed in early prostate disease and prostate cancer
To analyse ZnT4 protein expression in clinical samples, polyclonal antibodies were raised towards a 33mer peptide designed from the ZnT4 amino-terminus. Antibody specificity was tested using parental MFC and MFC infected with retroviruses encoding ZnT4. Western blot analysis of cell lysates probed with anti-ZnT4 antibodies detected a specific protein band of approximately 47 kDa visible only in lysates from ZnT4 retrovirus-infected MFC, but not in lysates from parental cells (Figure 4a ). In addition, immunoblot analysis of the prostate cancer cell lines LNCaP and PC-3 showed expression of the 47 kDa ZnT4 protein only in LNCaP cells (Figure 4b ), but not in PC-3 cells, consistent with the microarray data presented in Figure 1b (columns 169-176 vs 177-180).
Having confirmed the specificity of the anti-ZnT4 antibody, the expression of ZnT4 at the cellular level in benign and malignant prostate tissue was analysed by immunohistochemistry (IHC). A total of 165 benign and 326 malignant prostate tissue elements were analysed and the results are summarized in Table 1 . Anti-ZnT4 staining was restricted exclusively to the cytoplasm of Figure 5 ). Benign prostatic tissue displayed the highest levels of ZnT4 protein expression with strong (50%) or moderate (50%) staining seen in the normal prostate specimens (n ¼ 4; Figure 5a ) and strong staining seen in all of the benign prostatic hyperplasia (BPH) samples examined (n ¼ 9; Figure 5b ). Staining in prostate intraepithelial hyperplesia (PIN) (n ¼ 21) was mixed in intensity with staining being strong in three (14%), moderate in 10 (48%) and weak in eight (38%) of the samples tested (Figure 5c ). In contrast, the prostate cancer RP cohort (n ¼ 149) displayed a statistically significant decrease in the proportion of specimens with moderate or strong ZnT4 expression compared with benign tissues (Po0.01), with weak staining in 112 (75%), and moderate or strong staining in only 37 (25%) cases (Figure 5e, f) . Furthermore, a comparison of the levels of ZnT4 expression in the prostate cancers with neighbouring elements of hyperplasia showed that 92 (62%) of the cancers demonstrated a relative decrease in the intensity of staining (Figure 5g ), with expression in areas of hyperplasia adjacent to cancer showing moderate staining in 107 (80%) and strong staining in 16 (12%) cases examined. Although the number of cases was limited, the weak staining of ZnT4 in the more advanced cancers (LNM and D2) was notable (Figure 5h , i). There was no significant correlation on w 2 analysis between the intensity of ZnT4 immunostaining and other known predictors of prostate cancer outcome, including the Gleason score (P ¼ 0.84), seminal vesicle involvement (P ¼ 0.48), surgical margins (P ¼ 0.83) and preoperative PSA concentration (P ¼ 0.64).
Discussion
The inability of malignant prostate cells to maintain the high intracellular zinc concentrations of normal prostate epithelium has been implicated in neoplastic transformation; however, the exact mechanisms whereby this occurs are unknown. Previous studies examining the uptake and accumulation of zinc in LNCaP and PC-3 prostate cancer cells implicated the zinc transporter, hZIP1 as responsible for the rapid zinc uptake process seen in response to prolactin and testosterone in these cell lines . Here, we demonstrate the differential expression of ZnT4 in benign and malignant prostate tissue, suggesting a potential role for another zinc transporter in the regulation of this Figure 3 Demonstration of ZnT4 at the cell membrane. Western blot analysis of (a) whole-cell lysates of 25 mg per sample from mouse NIH3T3 cells and MFC that stably express ZnT4-HA, probed with an anti-HA antibody, and (b) biotinylated proteins that were affinity purified from the same cell lysates using streptavidin agarose gel and were then probed with an anti-HA antibody. The Western blot of the whole-cell lysates and of the biotinylated proteins demonstrate the same ZnT4-HA bands in both cell lines 
The expression of ZnT4 in benign and malignant prostate tissue was analysed by IHC using an anti-ZnT4 antibody. The intensity of ZnT4 staining was graded on the density of cytoplasmic granules as negative, weak (+), moderate (++) or strong (+++)
ZnT4 in prostate cancer SM Henshall et al process. The apparent inconsistency between the mRNA expression profiles for normal vs prostate cancer detected by microarray analysis (Figure 1 ) with the protein expression data determined by immunohistochemistry ( Figure 5 and Table 1 ) is most likely the result of differences in the epithelial cell content between the normal prostate samples and the prostate cancers, since there was no detectable ZnT4 staining in the stroma. To date, two distinct families of zinc transporter proteins have been identified in mammals: the ZnT and ZIP proteins. ZnT proteins are members of the cation diffusion facilitator (CDF) family and function by either transporting zinc out of cells or by sequestering it into intracellular compartments, while ZIP proteins appear to be involved in the cellular uptake of zinc. The ZNT family of mammalian zinc transporters, of which there are now six members, share similar structures consisting of six transmembrane domains and a histidine-rich cytoplasmic loop, but differ from each other in their tissue specificity and intracellular location (McMahon and Cousins, 1998; Murgia et al., 1999; Huang et al., 2002; Kambe et al., 2002) . ZNT1 is located at the plasma membrane and functions as a zinc efflux transporter (Palmiter and Findley, 1995) , while ZNT2 and ZNT3 are thought to be involved in zinc sequestration in endosomal vesicles (Palmiter et al., 1996a, b) . ZnT4 was first identified as the gene responsible for the impaired transport of zinc into the milk of the 'lethal milk' mouse (Huang and Gitshier, 1997) . A premature termination codon in ZnT4 resulted in a marked reduction in the milk zinc levels demonstrating that ZnT4 was essential for zinc efflux from mammary epithelial cells. More recent data demonstrating an association of ZnT4 with vesicles containing milk proteins support this view (Michalczyk et al., 2002) . Previous studies have implied that ZnT4 (Murgia et al., 1999 ) is located to endosomal vesicles, although a subpopulation of ZnT4-containing vesicles also contained the transferrin receptor that recycles between the endosomal compartment and the plasma membrane (Murgia et al., 1999) . The punctate cytoplasmic IHC staining seen in prostate tissue and the immunoflourescence studies performed on ZnTh infected overexpressing PC-3 prostate cancer cells are consistent with the intracytoplasmic vesicular location of ZnT4 described in ZnT4 in prostate cancer SM Henshall et al the rat intestine (Murgia et al., 1999) and the more detailed studies on subcellular localization to the trans-Golgi network and the endosomal compartment that it shares with ZnT6 (Huang et al., 2002) . However, our biotinylation studies suggest the presence of ZnT4 at the plasma membrane, indicating membrane cycling between endosomal vesicles and the cell membrane. While other authors share this view (Huang et al., 2002; Michalczyk et al., 2002) , clear demonstration of cell surface expression has, to date, been confined to overexpression studies with no detectable cell membrane labelling in PMC42 breast cancer (Michalczyk et al., 2002) , or LNCaP prostate cancer cells (date not shown). Indeed, clear delineation of plasma membrane staining may be confounded because ZnT4 may be constantly recycling. Thus, while the exact function of ZnT4 in the prostate remains unknown, our results are consistent with a role in the transport of cytoplasmic zinc into the Golgi apparatus, the vesicular compartment and potentially in efflux of zinc (Huang et al., 2002) .
Normal and hyperplastic prostate tissues accumulate the highest levels of zinc of any soft tissue in the body. Zinc levels in prostate cancer cells are markedly decreased compared to levels seen in nonmalignant cells (Zaichick et al., 1997) . In addition, zinc exhibits an inhibitory effect on the growth of prostate cancer cells (Liang et al., 1999) . Zinc may inhibit the development and growth of prostate cancer by inhibiting citrate metabolism and by stimulating mitochondrial apoptogenesis. The accumulation of high levels of intramitochondrial zinc directly inhibits m-aconitase activity and subsequently, the oxidation of citrate by prostate epithelial cells (Costello et al., 1997) . Zinc also triggers the release of mitochondrial cytochrome c and the subsequent activation of the proapoptotic caspases 9 and 3 (Feng et al., 2000) . Thus, changes in intracellular zinc concentration and distribution could promote cell growth and proliferation by loss of proapoptotic activity. This conclusion is supported by the findings of another recent study which showed that physiological levels of zinc inhibited activation of nuclear factor (NF)-kB transcription factor in PC-3 prostate cancer cells and resulted in reduced expression of the antiapoptotic protein c-IAP2 (Uzzo et al., 2002) .
High levels of zinc in the prostate are also associated with antimicrobial activities (Cho et al., 2002) . Thus, since an infectious aetiology has been proposed for prostate cancer, modulation of intracellular zinc levels in prostate cancer cells may also increase the risk of microbial infection. This hypothesis is supported by the recent findings that mutations in the macrophage scavenger receptor 1 gene or MSR1 and in 2 0 -5 0 -oligoadenylate(2-5A)-dependent RNase 1 (RNA-SEL), genes with potential roles in the eradication of certain pathogens, may be associated with increased risk of prostate cancer Xu et al., 2002) .
Interestingly, another member of the Znt family, ZnT5, is also expressed at high levels in human prostate tissue (Inoue et al., 2002) . Further understanding of the consequences of altered levels of ZnT4 and ZnT5 in the prostate and any potential role they may have in the decreased accumulation of zinc levels in prostate cancer is likely to be important in understanding the role of zinc physiology in the progression of this disease.
Materials and methods
Patient population
In all, 149 formalin-fixed, paraffin-embedded RP specimens were obtained from the archives of the Department of Anatomical Pathology at St Vincent's Hospital, Sugerman Hampson Macquarie Pathology (Sydney, Australia) and Douglass Hanly Moir Pathology (Sydney, Australia) for incorporation into tissue arrays for high-throughput immunohistochemistry (IHC). These 149 specimens are part of a previously described group of 732 patients (Quinn et al., 2001) and represent those patients with the most complete follow-up information and for whom paraffin-embedded tissue was available at the time of the study. A specimen cohort of fresh-frozen tissue from 74 patients treated with RP for clinically localized prostate cancer at St Vincent's Hospital, Sydney between 1996 and 2000 was also collected for the purpose of transcript profiling (median follow-up, 28.3 months, range 4.9-95.2 months). Additionally, tissue from nine patients with BPH, five patients with pelvic lymph node metastases (LNM) collected at RP and five prostate cancer specimens from previously untreated patients with bony metastatic disease (defined as D2 specimens) who underwent transurethral resection of the prostate were assessed. Normal prostate tissue was collected from four cadaveric organ donors (age range of 17-33 years). The NBA specimens that underwent transcript profiling were collected from 164 fresh-frozen samples harvested at the time of cadaveric organ donation. All of the normal body tissues were 3-5 h postmortem. The paraffin-embedded tissue comprising the NBA in the tissue microarrays was collected from tissues excised during surgery for a variety of pathological conditions. Each specimen described here was collected from a separate case. This project was approved by the St Vincent's Campus Human Research Ethics Committee (H00/088).
Cell lines and xenografts
EB colon cancer cells were generously provided by Sanford Markowitz (Case Western University, Cleveland, OH, USA). All other human cancer cell lines used in this study were obtained from the ATCC (Manassas, VA, USA). The mouse fibroblast cell (MFC) line used in this study has the following ATCC designation: BLK SV HD.2 A.5R A.3R.1. All the cell lines were maintained in DMEM with 10% fetal calf serum. Xenograft tumours were generated by passaging a minimum of 3 Â 10 6 cells subcutaneously in severe combined immunodeficient mice. Cells and xenografts were harvested in Trizol (Life Technologies, Rockville, MD, USA) reagent for transcript profiling.
Transcript profiling
Total RNA was extracted from the fresh-frozen specimens with Trizol reagent (Life Technologies, Rockville, MD, USA). Only RNA of acceptable quality as assessed by the presence of 28S and 18S RNAs was used for gene expression ZnT4 in prostate cancer SM Henshall et al profiling. cDNA was generated by reverse transcription using a primer containing oligo(dT) and a T7 promoter sequence. The cDNAs were then in vitro transcribed in the presence of biotinylated nucleotides (Bio-11-CTP and Bio-16-UTP) using the T7 MEGAscript kit (Ambion, Austin, TX, USA). The biotinylated targets were hybridized to the Eos Hu03, a customized Affymetrix GeneChip s (Affymetrix, Santa Clara, CA, USA) oligonucleotide array comprising over 59 000 oligonucleotide probesets for the interrogation of a total of 46 000 gene clusters that were based on the first draft of the human genome. Hybridization signals were visualized using phycoerythrin-conjugated streptavidin (Molecular Probes, Eugene, OR, USA). Normalization of the data was performed by fitting gene expression profiles to a model distribution derived from a large body of empirical data. Expression ratios of genes in the 74 prostate cancer specimens compared to the NBA were calculated using the average intensity results from the oligonucleotide arrays.
Protein analysis
To express ZnT4 in heterologous cells (NIH 3T3, MFC, PC-3), ZnT4 cDNA was cloned into the Phoenix retroviral constructs (Nolan Laboratories, Stanford, CA, USA). Retrovirus was generated in Cos7 cells and was used to infect heterologous cells, which were selected in blastocidin (10 mg/ml) for 2 weeks to generate stable cell lines. For protein expression, cells were fixed in 4% formaldehyde and permeabilized on glass slides in 0.5% Triton X-100, stained with antihaemagglutinin (HA)-tag antibodies and then visualized with Alexa-Red secondary antibodies (Molecular Probes, Eugene, OR, USA) under a fluorescence microscope. Cell-surface localization was performed using 100 mm dishes of confluent cell-surfacelabelled infected cells with impermeant EZ-Link TM Sulfo-NHS-SS-Biotin (Pierce, Rockford, IL, USA). Biotinylated cell surface proteins were affinity purified using Ultra-Link TM -Plus Immobilized Streptavidin agarose gel (Pierce, Rockford, IL, USA), released into boiling sodium dodecyl sulphate (SDS) and dithiothreitol-containing sample buffer and were identified by Western blotting using anti-HA tag antibodies.
Rabbit polyclonal antiserum to ZnT4 was generated against the amino-terminal peptide KDDAPLFLNDTSAFEFS-DEAGDEGLSRFNKLRC coupled to maleimide-activated ovalbumin (ImjectOva, Pierce) via the reactive side chain on the carboxyl-terminal Cys residue. Antibodies were affinity purified using protein A-sepharose (Amersham Pharmacia Biotech). To analyse ZnT4 expression in the LNCaP and PC-3 cell lines, cells were prepared from 100 mm dishes of 80-90% confluent cells and harvested in lysis buffer (50 mm HEPES pH 7.5, 150 mm NaCl, 10% glycerol, 1% Triton X-100, 1.5 mm MgCl 2 , 1mm EDTA, 10 mm pyrophosphate, 100 mm NaF and protease inhibitors 10 mg/ml aprotonin, 10 mg/ml leupeptin, 1 nm PMSF and 200 mm sodium orthovanadate) and immunoprecipitated with anti-ZnT4 antibody and protein A-sepharose beads (Zymed, Carlton, CA, USA). Immunoprecipitates were resolved using SDS-polyacrylamide gel electrophoresis, transferred to nitrocellulose and probed with anti-ZnT4 antibody. Horseradish peroxidase-linked Protein A (Zymed, Carlton, CA, USA) was used to detect anti-ZnT4 signal by enhanced chemiluminescent detection (Perkin-Elmer, Boston, MA, USA). Analysis of ZnT4 expression in whole-cell lysates of 25 mg per sample from parental MFCs and MFCs infected with ecotropic retrovirus encoding ZnT4-HA was performed by Western blotting using anti-ZnT4 antibodies.
Tissue microarrays
Tissue core biopsies of 1.0 or 2.0 mm (two array formats used) were incorporated into medium-density tissue microarrays (Beecher Instruments, Silver Spring, MD, USA) employing the technique described by Kononen et al. (1998) . Haematoxylin and eosin-stained template sections of the RP paraffin donor blocks were marked up for areas of PIN, nodular hyperplasia and cancer by a histopathologist (JGK, JJT or C-SL) according to accepted criteria (Gleason and Mellinger, 1974; McNeal, 1997) . Using these sections as a guide, a core of PIN (where present), between one and two cores of nodular hyperplasia adjacent to cancer (p2 cm from the cancer) and between two and four cores of cancer were sampled from the paraffin donor blocks of each of the 149 RP specimens and incorporated directly into recipient array blocks. A core was included from each of the primary, secondary and tertiary Gleason patterns represented in the cancers. Sections of 4 mm were then cut from the recipient array blocks for use in IHC. Verification of the pathology of each tissue element in the NBA and RP tissue microarrays was performed by a histopathologist (JGK) from a section cut and stained with haematoxylin and eosin prior to immunostaining and then again at the time of scoring of the IHC. In total, we arrayed 373 elements (cores) of cancer, 165 elements of nodular hyperplasia adjacent to cancer, 22 elements of PIN and 190 elements of the NBA. Loss of tissue cores during the cutting and immunostaining procedures reduced the number of cores that could be assessed to 326 (Table 1) . The normal prostate, LNM specimens, D2 specimens and BM specimens were mounted as conventional tissue sections.
Immunohistochemistry
IHC staining for ZnT4 was performed on routinely processed, paraffin-embedded tissue specimens. Sections 4 mm of these specimens were cut, mounted on Superfrost Plus adhesion slides (Lomb Scientific, Sydney, Australia) and heated in a convection oven at 751C for 2 h to promote adherence to the slide. Paraffin-embedded pellets of LNCaP and PC-3 prostate cancer cell lines were used as positive and negative controls, respectively. Sections were dewaxed and rehydrated before unmasking in EDTA/citrate buffer and were then stained with anti-ZnT4 antibody. Anti-ZnT4 signal was detected using DAKO EnVision Plus Labeled Polymer (DAKO Corporation, Carpinteria, CA, USA) with liquid 3,3 0 -diaminobenzidine Plus (DAKO Corporation, Carpinteria, CA, USA) as substrate. Counterstaining was performed with haematoxylin and Scott's blueing solution. Immunostaining was assessed by two separate observers (LGH and JGK) for each case. Standardization of scoring was achieved by comparison of scores between LGH and JGK, and by conferencing, where any discrepancies were resolved by consensus. All ZnT4 immunostaining was cytoplasmic and the intensity of staining was graded on the density of cytoplasmic granules as negative, weak ( þ ), moderate ( þ þ ) or strong ( þ þ þ ).
Statistical analysis of the correlation between ZnT4 immunostaining with parameters of clinicopathological outcome was performed using w 2 -tests. A P-value of o0.05 was required for significance. Statistical analyses were performed using Statview 5.0 software (Abacus Systems, Berkeley, CA, USA).
